М. В. Беркут

ORCID: 0000-0002-6276-1716
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Prostate Cancer Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Urological Disorders and Treatments
  • Ureteral procedures and complications
  • Urinary and Genital Oncology Studies
  • Urinary Tract Infections Management
  • Renal cell carcinoma treatment
  • Enhanced Recovery After Surgery
  • Cancer, Lipids, and Metabolism
  • COVID-19 and healthcare impacts
  • Cardiac, Anesthesia and Surgical Outcomes
  • Molecular Biology Techniques and Applications
  • Urinary Bladder and Prostate Research
  • Myofascial pain diagnosis and treatment
  • Urologic and reproductive health conditions
  • Pelvic floor disorders treatments
  • Diabetic Foot Ulcer Assessment and Management
  • MicroRNA in disease regulation
  • Mathematical Biology Tumor Growth
  • Radiomics and Machine Learning in Medical Imaging
  • Extracellular vesicles in disease
  • Hemostasis and retained surgical items
  • Abdominal Surgery and Complications
  • Multiple and Secondary Primary Cancers

Ministry of Health of the Russian Federation
2019-2025

Research Medical Center
2023-2025

Institute of Oncology NN Petrov
2021-2024

Candid
2019

Marymount University
2019

First Pavlov State Medical University of St. Petersburg
2019

Karaganda Medical University
2014

Введение. Частота олигометастатического поражения костей скелета в онкоурологии может варьировать зависимости от типа рака и стадии заболевания: при раке предстательной железы почки олигометастазы кости могут быть обнаружены у 20-30 % пациентов первичном обращении гораздо реже уротелиальном раке. Паллиативное применение метастаз-направленной терапии виде чрескожной криоаблации олигометастазов направлено на контроль болевого синдрома улучшение качества жизни пациентов. Цель. Изучение влияния...

10.37469/0507-3758-2024-70-6-1142-1149 article RU cc-by-nc-nd Voprosy Onkologii 2025-01-22

BACKGROUND: Robot-assisted radical prostatectomy (RARP) offers advantages over open and laparoscopic approaches, including superior visualization enhanced surgeon ergonomics. This study analyzed the short-term outcomes of first RARP performed at N.N. Petrov National Medical Research Center Oncology, comparing them with (LRP). AIM: To compare LRP in patients clinically localized prostate cancer low favorable intermediate risk. MATERIALS AND METHODS: The included who underwent (RP) for risk...

10.17816/uroved631870 article EN Urology reports (St - Petersburg) 2025-02-06

Background . Radical cystectomy (RC) remains the primary surgical method for treating bladder cancer. Minimally invasive techniques, such as laparoscopic and robot-assisted cystectomy, are becoming increasingly popular due to their advantages, but they have limitations related tumor features patients’ clinical characteristics. To confirm benefits of minimally RC address existing limitations, more extensive carefully controlled studies necessary. Aim evaluate 10-year oncological outcomes...

10.17650/1726-9776-2024-20-4-60-74 article EN Cancer Urology 2025-02-28

Background Standard 24-h antibiotic prophylaxis (AP) is widely employed to minimize the risk of infection complications (ICs) within 30 days following a radical cystectomy (RC). However, considerable variety protocols do not prevent high ICs rate after surgery (37–67%). Therefore, antibiotic's type and its duration are still controversial for AP.(

10.1080/20905998.2024.2373399 article EN cc-by-nc Arab Journal of Urology 2024-07-03

BACKGROUND: Standard 24-hour antibiotic prophylaxis is widely employed to minimize the risk of infection complications within 30 days following radical cystectomy. However, a considerable variety protocols and drug combinations don’t prevent high complication rate, ranging from 37 67%. This paper presents interim analysis MACS clinical trial, comparing regimens by duration. OBJECTIVE: To evaluate rate cystectomy standard (Group A) with prolonged 120-hour regimen B). METHODS: Patients were...

10.3233/blc-240012 article EN cc-by-nc Bladder Cancer 2024-07-16

Clinical Practice Points•One-half of patients with renal cell carcinoma infected severe acute respiratory syndrome coronavirus 2 required hospitalization.•Eastern Cooperative Oncology Group performance status could be negatively changed in these patients.•The mortality rate is higher than people without cancer.•Some have progression during infection. •One-half

10.1016/j.clgc.2020.07.007 article EN other-oa Clinical Genitourinary Cancer 2020-07-16

Background: The development of new non-invasive markers for prostate cancer (PC) diagnosis, prognosis, and management is an important issue that needs to be addressed decrease PC mortality. Small extracellular vesicles (SEVs) secreted by gland or cells into the plasma are considered next-generation diagnostic tools because their chemical composition might reflect development. population extremely heterogeneous. study aimed explore a approach prostate-derived SEV isolation followed vesicular...

10.3390/life13040885 article EN cc-by Life 2023-03-27

Рак мочевого пузыря (РМП) занимает 10 место в структуре онкологической заболеваемости мире, ежегодно регистрируется 573000 новых случаев этого заболевания и 213000 смертей [1]. У 25–30 % больных РМП при первичном обращении выявляется опухоль, инвазирующая мышечный слой глубже, где золотым стандартом лечения является радикальная цистэктомия (РЦЭ), ассоциированая с высоким уровнем развития периоперационных отдаленных осложнений [2].
 Цель исследования. Изучить частоту инфекционных период...

10.37469/0507-3758-2023-69-3-415-421 article RU cc-by-nc-nd Voprosy Onkologii 2023-06-30

Abstract Background To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of vaccination in Russian patients with genitourinary (GU) malignancies. Aim analysis was describe the characteristics infection course as well preliminary efficacy Gam-COVID-Vac vaccine active GU Methods Patients were retrospectively identified at nine cancer centers different regions. included if diagnosed by a polymerase chain reaction. Data from additional cancers who had positive...

10.1186/s13045-021-01205-z article EN cc-by Journal of Hematology & Oncology 2021-11-13

The study objective: estimation of two group patients, treated in N.N. Petrov National Medical Research Center Oncology with renal cell carcinoma. Materials and methods. 1st include patients standard postsurgical care management after open resection lumbotomy access warm ischemia. 2nd the same minimally invasive surgeries fast track elements under induced hypotension. We analysed preparation patient for surgery, differences treatment management, frequencies pain severity, complications,...

10.17650/1726-9776-2019-15-3-47-55 article EN Cancer Urology 2019-10-09

Background. Currently, there are sufficient data on the favorable role of fast track program course postoperative period. Nevertheless, these protocols being already included in standards surgical treatment many cancers is not clear to date oncourology general and prostate cancer (PC). Objective: determine effect elements for results patients after radical prostatectomy. Materials methods. 86 minimally invasive (laparoscopic or endoscopic extraperitoneal) prostatectomies were performed...

10.17650/1726-9776-2016-12-4-60-69 article EN Cancer Urology 2016-01-01

Введение. Выбор оптимального периоперационного лекарственного лечения локализованного уротелиального рака (УР) опирается на клинические и морфологические особенности опухоли, а также соматический статус пациента. В медицинской практике отсутствуют предиктивные биомаркеры, способные сократить избыточное лечение пациентов выявить заранее случаи, которые не будут отвечать проводимую терапию. Цель. Данное исследование направлено оценку безрецидивной (БРВ) общей выживаемости (ОВ) у с УР в...

10.37469/0507-3758-2024-70-4-685-695 article RU Voprosy Onkologii 2024-09-06

Targeted treatment of advanced or metastatic urothelial carcinomas (UCs) requires the identification druggable mutations. This study describes development a 3' Rapid Amplification cDNA Ends (3' RACE)-based targeted RNA sequencing panel which accounts for status all genes relevant to UC treatment, namely,

10.3390/ijms252212126 article EN International Journal of Molecular Sciences 2024-11-12

Стандартная 24‑часовая антибиотикопрофилактика (АП) широко используется для минимизации риска осложнений с инфекцией в течение 30 дней после радикальной цистэктомии (РЦЭ). Однако значительное разнообразие протоколов, комбинаций антибактериальных препаратов и продолжительность назначения не предотвращают высокий уровень инфекционных операции, частота которых может достигать 37–67 %. Целью настоящего исследования является оценка развития период РЦЭ хирургическом стационаре, работающем по...

10.18027/2224-5057-2024-14-3s1-63-71 article RU cc-by Malignant tumours 2024-11-18

Introduction. The results of genomic profiling muscle-invasive bladder cancer (BC) based on messenger RNA (mRNA) extraction showed significant molecular variety the tumors underlying wide spectrum clinical manifestations and responses to traditional treatment methods. However, despite valuableness mRNA for understanding biological behavior tumor, its implementation in routine practice is complicated due technological complexity high cost sequencing. Therefore, determination BC subtype...

10.17650/2313-805x-2024-11-4-102-113 article EN cc-by Advances in molecular oncology 2024-12-10

Objective: to assess safety, pathological response rate, and long-term oncologic outcomes of radical prostatectomy (RP) after neoadjuvant chemotherapy using docetaxel in prostate cancer (PCa) patients high very risk groups. Materials methods: 86 with PCa (PSA>20 ng/ml, Gleason score 8 more, or clinical stage cT2c more) were included, among them 46 received (NCGT/RP group) treatment followed by RP 40 only. a median follow-up 11.4 years RP. Neoadjuvant included 3-weekly (75 mg/m2 for up 6...

10.37469/0507-3758-2019-65-5-726-735 article EN cc-by-nc-nd Voprosy Onkologii 2019-05-01

T olsotogo St., Saint Petersburg 197022, Russia Backgr ound. Prostate cancer (PCa) of a high and very risk is potentially fatal disease that requires an active multimodal approach, including the use neoadjuvant drug treatment. As option for this treatment chemohormonal therapy (NCHT) followed by radical prostatectomy (RPE). However, data on oncological results such patients are still limited role in high-risk PCa remains not fully understood. Objective: to assess with localized locally...

10.17650/1726-9776-2020-16-1-54-63 article EN Cancer Urology 2020-04-23

Introduction The coronavirus pandemic (COVID-19) had a significant impact on the global healthcare sector and provoked current oncological care standards revision, including in urological oncology All changes have affected directly elective outpatient inpatient surgical through search for priority evidence-based treatment option cancer diseases during tense epidemiological period Aim aim of this study was to assess short-term results service background COVID-19 first wave Materials methods...

10.29188/2222-8543-2020-12-3-16-24 article RU cc-by Experimental and Сlinical Urology 2020-09-29

Background . High-risk prostate cancer (PCa) occurs in 15-25 % of newly diagnosed cases and is a life-threatening condition that requires active treatment. In recent years, the percentage high-risk PCa has significantly increased, as well number prostatectomies performed patients with unfavorable morphologic features. However, group criteria are not fully defined yet. According to various medical associations, locally advanced or localized disease may have high risk progression. Study...

10.17650/1726-9776-2021-17-2-54-61 article EN Cancer Urology 2021-07-25
Coming Soon ...